Protocol Ledger

NCT04535544 · Phase II · COMPLETED

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Interventional Phase II clinical trial protocol NCT04535544 sponsored by Johnson & Johnson / Janssen in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-17 Enrollment: 52 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04535544
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)52 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04535544
Protocol FieldVerified Registry Value
NCT IdentifierNCT04535544
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment52 participants (ACTUAL)
Registered Start Date2020-09-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04535544
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
Massachusetts General HospitalBoston, MAOpen Hospital Dossier ->
Royal Prince Alfred HospitalCamperdown, AustraliaOpen Hospital Dossier ->
Westmead HospitalWestmead, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI